Tid Tittel Kategori Vedlegg
26.06.2026
16:40
Resultater fra Ultimovacs' DOVACC fase II-studie bekrefter avslutningen av UV1-programmet, i tråd med tidligere kommunisert plan - -
26.06.2026
16:40
Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided - -
18.06.2026
11:08
Zelluna ASA: Disclosure of large shareholding STORAKSJONÆR AKS -
18.06.2026
00:28
Zelluna ASA - Mandatory notification of trade - Subscription and share lending in Private Placement INSIDEHANDEL INS
1
18.06.2026
00:21
Zelluna ASA: Private Placement and Retail Offering successfully placed - -
17.06.2026
16:46
Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data - -
07.05.2026
07:00
Zelluna ASA: First Quarter 2026 results -
2
07.05.2026
07:00
Zelluna ASA: Første kvartal 2026 - -
06.05.2026
23:18
Zelluna ASA aktiverer det første kliniske senteret for ZIMA-101studien, og markerer dermed oppstart av klinisk gjennomføring - -
06.05.2026
23:18
Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution - -
04.05.2026
17:58
Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation (corrected time) - -
04.05.2026
15:19
Zelluna ASA: Invitation to First Quarter 2026 results webcast Presentation - -
23.04.2026
09:37
Zelluna ASA - Annual General Meeting held on April 23, 2026 -
1
08.04.2026
11:25
Zelluna ASA - Disclosure of voting rights of Annual General Meeting STORAKSJONÆR AKS -
27.03.2026
10:01
Zelluna ASA - Mandatory notification of trade INSIDEHANDEL INS
1
26.03.2026
15:28
Zelluna to host Capital Markets Update 2026 -
1
26.03.2026
08:57
Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026 -
6
25.03.2026
07:00
Zelluna ASA [ZLNA]: Annual Report 2025 RAPPORT RAP
2
09.03.2026
08:00
Zelluna inngår samarbeid med Etcembly for AI-drevet TCR-utvikling - -
09.03.2026
08:00
Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering - -
20.02.2026
14:30
Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 første-i-menneske klinisk studie - -
20.02.2026
14:30
Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial - -
12.02.2026
07:00
Zelluna ASA: Fjerde kvartal 2025 - Viktig regulatorisk milepæl oppnådd med CTA-innlevering -
2
12.02.2026
07:00
Zelluna ASA: Fourth Quarter 2025 - Key regulatory milestone achieved with CTA Submission -
2
11.02.2026
08:00
Zelluna inngår avtale med Medpace om første kliniske studie - pasientdata ventes fra medio 2026 - -